Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from IpsenGlobeNewsWire • Thursday
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 08/22/24
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024GlobeNewsWire • 07/30/24
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)GlobeNewsWire • 07/15/24
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)GlobeNewsWire • 04/30/24
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024GlobeNewsWire • 04/29/24
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKEAccesswire • 03/22/24
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for PhenylketonuriaGlobeNewsWire • 03/22/24
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/14/24
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/14/24
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024GlobeNewsWire • 02/29/24
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid FormulationGlobeNewsWire • 02/21/24
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone CapsulesGlobeNewsWire • 02/02/24
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023GlobeNewsWire • 10/30/23
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product NitisinoneGlobeNewsWire • 10/04/23
Here's Why 'Trend' Investors Would Love Betting on Eton Pharmaceuticals, Inc. (ETON)Zacks Investment Research • 09/12/23